Authors
Amir Tirosh, Ediz S Calay, Gurol Tuncman, Kathryn C Claiborn, Karen E Inouye, Kosei Eguchi, Michael Alcala, Moran Rathaus, Kenneth S Hollander, Idit Ron, Rinat Livne, Yoriko Heianza, Lu Qi, Iris Shai, Rajesh Garg, Gökhan S Hotamisligil
Publication date
2019/4/24
Journal
Science translational medicine
Volume
11
Issue
489
Pages
eaav0120
Publisher
American Association for the Advancement of Science
Description
The short-chain fatty acid propionate is a potent inhibitor of molds that is widely used as a food preservative and endogenously produced by gut microbiota. Although generally recognized as safe by the U.S. Food and Drug Administration, the metabolic effects of propionate consumption in humans are unclear. Here, we report that propionate stimulates glycogenolysis and hyperglycemia in mice by increasing plasma concentrations of glucagon and fatty acid–binding protein 4 (FABP4). Fabp4-deficient mice and mice lacking liver glucagon receptor were protected from the effects of propionate. Although propionate did not directly promote glucagon or FABP4 secretion in ex vivo rodent pancreatic islets and adipose tissue models, respectively, it activated the sympathetic nervous system in mice, leading to secretion of these hormones in vivo. This effect could be blocked by the pharmacological inhibition of …
Total citations
201920202021202220232024173751644418